Saniona Expands Executive Team with Appointments of Chief Financial Officer, Chief Communications Officer and Chief Human Resources Officer

NEXT STORY
Press Release Oncology Venture’s Novel PARP Inhibitor Stenoparib (formerly 2X-121) Shows Anti-Viral Activity Against Coronavirus in Pre-Clinical Studies
PREV STORY
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Mateon Therapeutics Announces Encouraging Results from First Interim Analysis of Phase 2/3 FOCUS Study in Platinum-resistant Ovarian Cancer

No Significant CA4P Drug Safety Issues IdentifiedInitial Efficacy in Favor of CA4P, with 22% ...

author_avatar
NASDAQ Market News

Nya data för simeprevir kommer att presenteras vid EASL:s International Liver Congress 2016

Stockholm — Medivir AB (Nasdaq Stockholm: MVIR) meddelar idag att nya kliniska data för ...

author_avatar
NASDAQ Market News

Amarin and Mochida Announce Collaboration on Future Development of EPA-based Drug Products and Indications

BEDMINSTER, N.J. and DUBLIN, Ireland, June 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc ...

author_avatar
NASDAQ Market News